Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy

What is it about?

This study looked at the long-term effects of a drug called atacicept on patients with immunoglobulin A (IgA) nephropathy, a kidney disease where the immune system attacks the kidneys. Atacicept works by blocking two proteins, BAFF and APRIL, which play a key role in the disease._x000D_ In this study, patients who had previously taken atacicept or a placebo for 36 weeks continued treatment with atacicept for an additional 60 weeks. Researchers measured key outcomes such as levels of a harmful type of IgA, the presence of blood in urine, protein levels in urine, and kidney function. Over the 96-week period, the drug significantly reduced these disease markers. Kidney function remained stable, with only a small decline observed._x000D_ Atacicept was generally safe and well tolerated, with no major safety concerns. These results support further research, including a larger Phase 3 trial, and suggest that atacicept could be an important treatment for IgA nephropathy.

Featured Image